Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 201–300 of 1,000
Lei, B., Dawson, H. N., Wilson, B., Wang, H., Laskowitz, D. T., & James, M. L. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-103 · Cited by 81
“However, the failure of recent large clinical trials [5,6] may be the result of an inability to fully account for the influence of secondary injury from the neuroinflammatory response.”
BackgroundLee, S., Park, H. ‐., Ryu, W., Lee, J., Bae, H., Han, M., Lee, Y. ‐., Kwon, H., Kim, C. K., Park, E. ‐., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12140 · Cited by 73
“Thus, a large-sized trial for improvement of functional outcome through ICH expansion using recombinant factor VIIa was previously conducted; however, it failed to show any benefit [7,8].”
BackgroundBiancofiore, G., Blasi, A., de Boer, M. T., Franchini, M., Hartmann, M., Lisman, T., Liumbruno, G. M., Porte, R. J., Saner, F. H., Senzolo, M., et al. (2019) · Minerva Anestesiologica · doi:10.23736/s0375-9393.19.13468-2 · Cited by 72
Kuohn, L. R., Witsch, J., Steiner, T., Sheth, K. N., Kamel, H., Navi, B. B., Merkler, A. E., Murthy, S. B., & Mayer, S. A. (2022) · Stroke · doi:10.1161/strokeaha.121.037974 · Cited by 72
Self-citationDESTINY-S: Attitudes of Physicians Toward Disability and Treatment in Malignant MCA Infarction
Neugebauer, H., Creutzfeldt, C. J., Hemphill, J. C., Heuschmann, P. U., & Jüttler, E. (2014) · Neurocritical Care · doi:10.1007/s12028-014-9956-0 · Cited by 74
“Often this scale is dichotomized into favorable and unfavorable outcome, but no consensus exists on the optimal dichotomization point, and different studies have used different cut-points, often justified by severity of the condition being studied [10, 11].”
BackgroundHaemostatic drug therapies for acute spontaneous intracerebral haemorrhage
Salman, R. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005951.pub3 · Cited by 72
Yuan, Z. H., Jiang, J., Huang, W., Pan, J., Zhu, J., & Wang, J. Z. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.11.020 · Cited by 71
“Although reduction of the hematoma growth was confirmed in a large Phase III trial, the improvement in survival and functional outcomes were not found in this trial.(14) It is thus unknown whether the administration of rFVIIa improves general clinical outcomes.”
BackgroundMethodZhong, Q., Zhou, K., Liang, Q., Lin, S., Wang, Y., Xiong, X., Meng, Z., Zhao, T., Zhu, W., Yang, Y., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004340 · Cited by 75
Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects
Skolnick, B. E., Mathews, D. R., Khutoryansky, N., Pusateri, A. E., & Carr, M. E. (2010) · Blood · doi:10.1182/blood-2009-11-253492 · Cited by 70
Self-citationRedefining Hematoma Expansion With the Inclusion of Intraventricular Hemorrhage Growth
Yogendrakumar, V., Ramsay, T., Fergusson, D. A., Demchuk, A. M., Aviv, R. I., Rodríguez‐Luna, D., Molina, C. A., Silva, Y., Dzialowski, I., Kobayashi, A., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.027451 · Cited by 70
Kuramatsu, J. B., Gerner, S. T., Lücking, H., Kloska, S. P., Schellinger, P. D., Köhrmann, M., & Huttner, H. B. (2013) · Critical Care · doi:10.1186/cc12827 · Cited by 73
“Based on the strong association of ICH volume and outcome, and in light of large hemostatic and blood pressure lowering trials failing to influence clinical endpoints after enrolling patients with ICH volumes up to 60 cm(3) [9,10], defining rather tighter volume cutoffs - as done in the ongoing CLEAR-IVH trial (ICH vo…”
BackgroundLow hemoglobin and hematoma expansion after intracerebral hemorrhage
Roh, D. J., Albers, D. J., Magid-Bernstein, J. R., Doyle, K. W., Hod, E. A., Eisenberger, A. B., Murthy, S. B., Witsch, J., Park, S., Agarwal, S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007820 · Cited by 69
“Brainstem location, n (%) 11 (4) 0 (0) 11 (6) 0.”
Recommendations for Clinical Trials in ICH
Participants, T. H. S. A. I. (. R., Selim, M. H., Hanley, D. F., Steiner, T., Christensen, H. K., Lafuente, J., Rodriguez, D., Keep, R. F., Anderson, C. S., Parry‐Jones, A., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.027882 · Cited by 70
Self-citationManagement of intracerebral hemorrhage
Thabet, A. M., Kottapally, M., & Hemphill, J. C. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63600-3.00011-8 · Cited by 74
“There were no differences in severe disability or mortality rates between the two groups even though rFVIIa did reduce hematoma expansion (Mayer et al., 2008).”
BackgroundKlebe, D. W., McBride, D. W., Flores, J. J., Zhang, J. H., & Tang, J. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9613-1 · Cited by 73
“Hemostatic therapies have also been investigated in clinical trials, such as recombinant factor VII, but despite showing promise in experimental studies, none have been clinically approved (Mayer et al. 2006, 2008; Diringer et al. 2010).”
The HEP Score: A Nomogram-Derived Hematoma Expansion Prediction Scale
Yao, X., Xu, Y., Siwila-Sackman, E., Wu, B., & Selim, M. H. (2015) · Neurocritical Care · doi:10.1007/s12028-015-0147-4 · Cited by 69
“reductions in hematoma expansion, but have not consistently shown improved clinical outcomes [5, 6].”
BackgroundWhen the Blood Hits Your Brain: The Neurotoxicity of Extravasated Blood
Stokum, J. A., Cannarsa, G. J., Wessell, A. P., Shea, P., Wenger, N., & Simard, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105132 · Cited by 71
Testai, F. D., & Aiyagari, V. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.06.001 · Cited by 81
Woo, C. H., Patel, N. V., Conell, C. A., Rao, V. A., Faigeles, B. S., Patel, M. C., Pombra, J., Akins, P. T., Axelrod, Y. K., Ge, I. Y., et al. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2012.12.002 · Cited by 73
How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage
Goodnough, L. T., & Shander, A. (2011) · Blood · doi:10.1182/blood-2010-11-316075 · Cited by 67
“Door to CT scan time, min 65 (30-90) 40 (25-85) .”
Association of Serum IL-6 (Interleukin 6) With Functional Outcome After Intracerebral Hemorrhage
Leasure, A. C., Kuohn, L. R., Vanent, K. N., Bevers, M. B., Kimberly, W. T., Steiner, T., Mayer, S. A., Matouk, C. C., Sansing, L. H., Falcone, G. J., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.032888 · Cited by 67
Self-citationKawano-Castillo, J. F., Ward, E., Elliott, A. M., Wetzel, J., Hassler, A., McDonald, M. M., Parker, S. A., Archeval-Lao, J. M., Tremont, C., Cai, C. C., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.003826 · Cited by 66
Time Course of Early Postadmission Hematoma Expansion in Spontaneous Intracerebral Hemorrhage
Ovesen, C., Christensen, A. F., Krieger, D. W., Rosenbaum, S., Havsteen, I. B., & Christensen, H. (2014) · Stroke · doi:10.1161/strokeaha.113.003608 · Cited by 66
Recruitment and Retention of Patients into Emergency Medicine Clinical Trials
Cofield, S. S., CONWIT, R. A., Barsan, W. G., & Quinn, J. (2010) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2010.00866.x · Cited by 65
Guías de actuación clínica en la hemorragia intracerebral
Rodríguez‐Yáñez, M., Castellanos, M., Freijo, M. D. M., Fernández, J. C. L., Martí‐Fábregas, J., Nombela, F., Simal, P., Castillo, J., Díez‐Tejedor, E., Fuentes, B., et al. (2011) · Neurología · doi:10.1016/j.nrl.2011.03.010 · Cited by 85
Fibrinolysis for acute pulmonary embolism
Piazza, G., & Goldhaber, S. Z. (2010) · Vascular Medicine · doi:10.1177/1358863x10380304 · Cited by 69
“In a randomized controlled trial of 841 patients with spontaneous intracerebral hemorrhage, recombinant factor VIIa reduced the volume of the hematoma but did not improve survival or functional outcome.(49) Use of recombinant factor VIIa to reverse bleeding after fibrinolysis in the prothrombotic setting of acute PE m…”
BackgroundDepressed Mood after Intracerebral Hemorrhage: The FAST Trial
Christensen, M. C., Mayer, S. A., Ferran, J.-M., & D, B. M. K. M. (2009) · Cerebrovascular Diseases · doi:10.1159/000202012 · Cited by 66
“In addition, no studies to our knowledge have examined poststroke depression/depressed mood in a pure ICH population.In this study, we report the results of the depressed-mood and QoL assessment conducted in a recent multinational, placebo-controlled clinical trial investigating the effect of recombinant activated fac…”
ResultSelf-citationLiu, J., Nie, X., Gu, H., Zhou, Q. G., Sun, H., Tan, Y., Liu, D., Zheng, L., Zhao, J., Wang, Y., et al. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-000942 · Cited by 64
Rodríguez‐Luna, D., Dowlatshahi, D. D., Aviv, R. I., Molina, C. A., Silva, Y., Dzialowski, I., Lum, C., Członkowska, A., Boulanger, J.-M., Kase, C. S., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.003007 · Cited by 64
Perihematomal Edema Expansion Rates and Patient Outcomes in Deep and Lobar Intracerebral Hemorrhage
Grunwald, Z., Beslow, L. A., Urday, S., Vashkevich, A., Ayres, A. M., Greenberg, S. M., Goldstein, J. N., Leasure, A. C., Shi, F., Kahle, K. T., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-016-0321-3 · Cited by 70
“One of the largest studies of ICH ever completed, the INTERACT-2 trial, demonstrated improved functional outcomes in an ordinal analysis with intensive blood pressure management but found no reduction in absolute or relative hematoma growth [31].”
Chen, Q., Zhu, D., Liu, J., Zhang, M., Xu, H., Xiang, Y., Zhan, C., Zhang, Y., Huang, S., & Yang, Y. (2020) · Academic Radiology · doi:10.1016/j.acra.2020.02.021 · Cited by 70
Stein, D. M., Dutton, R. P., Kramer, M. E., & Scalea, T. M. (2009) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e318191bc8a · Cited by 63
Off-Label Recombinant Factor VIIa Use and Thrombosis in Children: A Multi-Center Cohort Study
Witmer, C. M., Huang, Y.-S. V., Lynch, K. G., Raffini, L. J., & Shah, S. S. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.10.038 · Cited by 62
“This large trial used the direct clinical end point of severe disability or death.(31) Patients were randomly assigned to receive placebo, 20 mg/kg of rFVIIa, or 80 mg/kg of rFVIIa.”
Rincón, F., Friedman, D. P., BELL, R. D., Mayer, S. A., & Bray, P. F. (2014) · International Journal of Stroke · doi:10.1111/ijs.12220 · Cited by 63
Self-citationSemi-automated method for brain hematoma and edema quantification using computed tomography
Bardera, A., Boada, I., Feixas, M., Remollo, S., Blasco, G., Silva, Y., & Pedraza, S. (2009) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2009.02.001 · Cited by 63
Critical Care Management of Intracerebral Hemorrhage
Chan, S. L., & Hemphill, J. C. (2014) · Critical Care Clinics · doi:10.1016/j.ccc.2014.06.003 · Cited by 62
“were the same in all treatment groups, arterial events were more frequent in those receiving 80 mg/kg of rFVIIa versus placebo.(50) Thus, the use of rFVIIa is not routinely recommended for any category of patients with ICH.”
Cerebral Ischemic Reperfusion Injury Following Recanalization of Large Vessel Occlusions
Al‐Mufti, F., Amuluru, K., Roth, W., Nuoman, R., El-Ghanem, M. H., & Meyers, P. M. (2017) · Neurosurgery · doi:10.1093/neuros/nyx341 · Cited by 64
New and expanding ventricular hemorrhage predicts poor outcome in acute intracerebral hemorrhage
Yogendrakumar, V., Ramsay, T., Fergusson, D. A., Demchuk, A. M., Aviv, R. I., Rodríguez‐Luna, D., Molina, C. A., Silva, Y., Dzialowski, I., Kobayashi, A., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008007 · Cited by 62
Prabhakaran, S., Herbers, P. M., Khoury, J. C., Adeoye, O. M., Khatri, P., Ferioli, S., & Kleindorfer, D. (2015) · Stroke · doi:10.1161/strokeaha.114.008006 · Cited by 64
Naidech, A. M., Grotta, J. C., Elm, J., Janis, S., Dowlatshahi, D. D., Toyoda, Ḱ., Steiner, T., Mayer, S. A., Khanolkar, P., Denlinger, J., et al. (2021) · International Journal of Stroke · doi:10.1177/17474930211042700 · Cited by 61
“rFVIIa activates coagulation and platelet activity(13) and reduced HE in phase II and phase III trials.(8,14,15) A trial of tranexamic acid found a small reduction in HE.”
BackgroundSelf-citationPasternak, J. J., & Lanier, W. L. (2009) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000048 · Cited by 62
The acute management of intracerebral hemorrhage
Flower, O., & Smith, M. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e328342f823 · Cited by 75
Advances in the management of intracerebral hemorrhage
Kuramatsu, J. B., Huttner, H. B., & Schwab, S. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1040-y · Cited by 66
“…RCTs investigating possible effects of hemostatic treatment with a recombinant activated factor VII showed a reduction of HG, those studies failed to influence a clinical endpoint (FAST trial) which has led to great disillusionment amongst neuro-critical-care physicians (Mayer et al. 2008).”
Intracranial Hemorrhage: Diagnosis and Management
Freeman, W. D., & Aguilar, M. I. (2012) · Neurologic Clinics · doi:10.1016/j.ncl.2011.09.002 · Cited by 65
Lauer, A., Pfeilschifter, W., Schaffer, C. B., Lo, E. H., & Foerch, C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70049-8 · Cited by 65
Niessner, A., Tamargo, J., Morais, J., Koller, L., Wassmann, S., Husted, S. E., Torp-Pedersen, C., Kjeldsen, K., Lewis, B. S., Drexel, H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv676 · Cited by 59
“Although pro-haemostatic agents may also limit the extent of bleeding in patients with ICH, their effect on mortality and disability is unknown.(39)”
BackgroundRecombinant activated factor VII: 30 years of research and innovation
Hedner, U. K. E. (2015) · Blood Reviews · doi:10.1016/s0268-960x(15)30002-3 · Cited by 59
“[68] Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al.”
BackgroundGender and Age Interact to Affect Early Outcome after Intracerebral Hemorrhage
Umeano, O. A., Phillips‐Bute, B., Hailey, C. E., Sun, W. M., Gray, M. C., Wilson, B., McDonagh, D. L., Kranz, P. G., Laskowitz, D. T., & James, M. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081664 · Cited by 59
“Although factors that influence recovery from ICH have been explored in major clinical trials[5,6], the potential interaction of gender and age Table 2.”
BackgroundTreatment of individuals who cannot receive blood products for religious or other reasons
Scharman, C. D., Burger, D., Shatzel, J. J., Kim, E., & DeLoughery, T. G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24889 · Cited by 60
“This agent is FDAapproved for use in hemophilia and factor VII deficiency, but has been used off-label in other settings, including trauma, major surgeries (including cardiac,(88,89) pancreatic,(90,91) orthopedic,(92) and liver transplantation) and intracranial hemorrhage.(96) However, a 2012 Cochrane meta-analysis, w…”
Recent Advances in Nanomedicine for Ischemic and Hemorrhagic Stroke
Bonnard, T., Gauberti, M., de Lizarrondo, S. M., Campos, F., & Vivien, D. (2019) · Stroke · doi:10.1161/strokeaha.118.022744 · Cited by 61
for the BE FAST III Study Group, Luger, S., Jæger, H. S., Dixon, J., Bohmann, F. O., Schäefer, J. H., Richieri, S. P., Larsen, K., Hov, M. R., Bache, K. G., et al. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00931-5 · Cited by 59
Emergency Neurological Life Support: Intracerebral Hemorrhage
Hemphill, J. C., & Lam, A. M. (2017) · Neurocritical Care · doi:10.1007/s12028-017-0453-0 · Cited by 58
“rFVIIa has been shown to decrease hematoma growth in non-coagulopathic ICH patients, but this did not translate into improved clinical outcome [33].”
BackgroundQuantitative CT Densitometry for Predicting Intracerebral Hemorrhage Growth
Barras, C. D., Tress, B. M., Christensen, S., Collins, M. L., Desmond, P. M., Skolnick, B. E., Mayer, S. A., & Davis, S. M. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3375 · Cited by 61
“Hemostatic studies by using rFVIIa have demonstrated approximately 50% less growth compared with a placebo.(2,3) Despite this potent biologic effect, discordant clinical results were found between an initial phase IIb proof-of-concept trial(2) and a pivotal phase III trial.”
ResultSelf-citationManagement of Adult Jehovah's Witness Patients with Acute Bleeding
Berend, K., & Levi, M. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.06.028 · Cited by 57
Fam, M. D., Hanley, D. F., Stadnik, A., Zeineddine, H. A., Girard, R., Jesselson, M., Cao, Y. J., Money, P. L., McBee, N. A., Bistran-Hall, A. J., et al. (2017) · Neurosurgery · doi:10.1093/neuros/nyx123 · Cited by 60
Multiphase CT Angiography Improves Prediction of Intracerebral Hemorrhage Expansion
Rodríguez‐Luna, D., Coscojuela, P., Rodríguez‐Villatoro, N., Juega, J., Boned, S., Muchada, M., Pagola, J., Rubiera, M., Ribó, M., Tomasello, A., et al. (2017) · Radiology · doi:10.1148/radiol.2017162839 · Cited by 57
Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Salman, R. A., Law, Z. K., Bath, P. M., Steiner, T., & Sprigg, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005951.pub4 · Cited by 57
Self-citationKamat, P., Kunde, S. S., Vos, M., Vats, A., Gupta, N. A., Heffron, T. G., Romero, R., & Fortenberry, J. D. (2011) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e31820ac08f · Cited by 58
“Studies have shown that frequent use of activated recombinant factor VII in high dose scan results in life-threatening arterial and venous thromboembolism (21, 22).”
BackgroundNew parenteral anticoagulants in development
Gómez‐Outes, A., Suárez-Gea, M. L., Lecumberri, R., Rocha, E. A. V., Pozo-Hernández, C., & Vargas, E. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710387808 · Cited by 56
“2010] and the risk of thrombosis [Gill et al. 2009; Mayer et al. 2008], further studies are required”
BackgroundThe Practical Management of Intracerebral Hemorrhage Associated with Oral Anticoagulant Therapy
Masotti, L., Napoli, M. D., Godoy, D. A., Rafanelli, D., Liumbruno, G. M., Koumpouros, N., Landini, G., Pampana, A., Cappelli, R., Poli, D., et al. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00595.x · Cited by 61
Predictors of Late Neurological Deterioration After Spontaneous Intracerebral Hemorrhage
Sun, W., Pan, W., Kranz, P. G., Hailey, C. E., Williamson, R. A., Sun, W. M., Laskowitz, D. T., & James, M. L. (2013) · Neurocritical Care · doi:10.1007/s12028-013-9894-2 · Cited by 57
Fingas, M., Penner, M., Silasi, G., & Colbourne, F. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.007 · Cited by 56
“, 2005) and the use of rFVIIa (Mayer et al., 2008), support this assertion.”
Koschnitzky, J. E., Keep, R. F., Limbrick, D. D., McAllister, J. P., Morris, J. A., Strahle, J. M., & Yung, Y. C. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0096-3 · Cited by 59
Arima, H., Huang, Y., Wang, J. G., Heeley, E. L., Delcourt, C., Parsons, M. W., Li, Q., Neal, B. C., Chalmers, J. P., Anderson, C. S., et al. (2012) · Stroke · doi:10.1161/strokeaha.112.651422 · Cited by 55
Warfarin and intracranial haemorrhage
Appelboam, R., & Thomas, E. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.05.001 · Cited by 58
Li, Q., Li, R., Zhao, L., Yang, X., Yang, W., Deng, L., Lv, X., Wu, G., Tang, Z., Wei, M., et al. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00958-8 · Cited by 55
Treatment of intracerebral hemorrhage: Current approaches and future directions
Zhao, W., Wu, C., Stone, C., Ding, Y., & Ji, X. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117020 · Cited by 59
Kase, C. S., & Hanley, D. F. (2021) · Neurologic Clinics · doi:10.1016/j.ncl.2021.02.002 · Cited by 59
Re-exploring Tumor Necrosis Factor Alpha as a Target for Therapy in Intracerebral Hemorrhage
Behrouz, R. (2016) · Translational Stroke Research · doi:10.1007/s12975-016-0446-x · Cited by 54
Treatment for intracerebral hemorrhage: Dawn of a new era
Seiffge, D. J., & Anderson, C. S. (2024) · International Journal of Stroke · doi:10.1177/17474930241250259 · Cited by 54
“6,7 Several randomized controlled trials of surgical treatment (i.e. different approaches to evacuation of parenchymal or intraventricular hematoma), 8–11 blood pressure (BP) control, 12,13 and hemostatic therapies, 14–16 resulted in either borderline significant or neutral results.”
BackgroundIntracerebral hemorrhage: getting ready for effective treatments
Rincón, F., & Mayer, S. A. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283352c01 · Cited by 56
Self-citationLo, W. D. (2011) · Journal of Child Neurology · doi:10.1177/0883073811408424 · Cited by 54
“The recombinant factor reduced hematoma growth in a phase 3 trial in adults but did not improve outcome, and the highest dose was associated with increased numbers of thromboembolic events.(47,48) Clinical seizures occur in a substantial number of children, with percentages ranging from 26% to 37%.”
BackgroundMittal, M. K., & LacKamp, A. N. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00210 · Cited by 54
“However, in this larger study, there was an excess in arterial thrombotic events and there was no overall clinical benefit, while the trend was toward greater death and disability in the treatment group with rFVIIa as compared to placebo (26–29 versus 24%) (128).”
BackgroundLin, Y., Stanworth, S. J., Birchall, J. E., Doree, C. J., & Hyde, C. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100408 · Cited by 53
“bined outcome of severe disability or death.(3) Common exclusion criteria were history of clotting and hemorrhagic dia thesis.”
BackgroundManagement of Intracerebral Hemorrhage: Update and Future Therapies
Kirshner, H. S., & Schrag, M. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01144-9 · Cited by 53
Update on Intracerebral Hemorrhage
Manno, E. M. (2012) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000415430.99394.3e · Cited by 63
A Telestroke Network Enhances Recruitment into Acute Stroke Clinical Trials
Switzer, J. A., Hall, C. E., Close, B., Nichols, F. T., Gross, H., Bruno, A., & Hess, D. C. (2010) · Stroke · doi:10.1161/strokeaha.109.566844 · Cited by 53
Caprio, F. Z., Maas, M. B., Rosenberg, N. F., Kosteva, A. R., Bernstein, R. A., Alberts, M. J., Prabhakaran, S., & Naidech, A. M. (2013) · Stroke · doi:10.1161/strokeaha.112.676890 · Cited by 56
Haemostatic drugs for traumatic brain injury
Perel, P., Roberts, I., Shakur‐Still, H., Thinkhamrop, B., Phuenpathom, N., & Yutthakasemsunt, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007877.pub2 · Cited by 53
RetractedLazo‐Langner, A., Lang, E., & Douketis, J. D. (2013) · Critical Care · doi:10.1186/cc12592 · Cited by 52
Ciura, V. A., Brouwers, H. B., Umeton, R. P., Ortiz, C. J., Rosand, J. M., Goldstein, J. N., Greenberg, S. M., Pomerantz, S. R., González, R., & Romero, J. M. (2014) · Stroke · doi:10.1161/strokeaha.114.005570 · Cited by 54
Oral Anticoagulant Therapy in Atrial Fibrillation Patients at High Stroke and Bleeding Risk
Potpara, T., & Lip, G. Y. H. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.003 · Cited by 58
Significance of Intraventricular Hemorrhage in Acute Intracerebral Hemorrhage
Chan, E., Anderson, C. S., Wang, X., Arima, H., Saxena, A., Moullaali, T. J., Heeley, E. L., Delcourt, C., Wu, G. G., Wang, J., et al. (2015) · Stroke · doi:10.1161/strokeaha.114.008470 · Cited by 52
Emergency Neurological Life Support: Intracerebral Hemorrhage
Andrews, C. M., Jauch, E. C., Hemphill, J. C., Smith, W. S., & Weingart, S. D. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9757-2 · Cited by 52
“rFVIIa has been shown to decrease hematoma growth in noncoagulopathic ICH patients, but this did not translate into improved clinical outcome [30].”
BackgroundSorimachi, T., Fujii, Y., Morita, K., & Tanaka, R. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.2.250 · Cited by 52
European Research Priorities for Intracerebral Haemorrhage
Steiner, T., Petersson, J., Salman, R. A., Christensen, H., Cordonnier, C., Csiba, L., Harnof, S., Krieger, D. W., Mendelow, D. A., Molina, C. A., et al. (2011) · Cerebrovascular Diseases · doi:10.1159/000330653 · Cited by 59
Self-citationJiang, C. Q., Guo, H., Zhang, Z., Wang, Y., Liu, S., Lai, J., Wang, T. J., Li, S., Zhang, J., Zhu, L., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3948921 · Cited by 55
“Most studies revealed that hemostasis with vitamin K antagonists, fresh frozen plasma (FFP), activated factor VII (rFVIIa), prothrombin complex (PCC), tranexamic acid, and aminocaproic acid targeted in the hematoma did not improve outcomes [227, 229, 230].”
Ruff, I., de Havenon, A., Bergman, D. L., Dugue, R., Frontera, J. A., Goldstein, J. N., Hemphill, J. C., Marulanda-Londoño, E. T., Prabhakaran, S., Richards, C. T., et al. (2024) · Stroke · doi:10.1161/str.0000000000000464 · Cited by 63
Therapeutic Strategies in Acute Intracerebral Hemorrhage
Brouwers, H. B., & Goldstein, J. N. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0091-8 · Cited by 55
“This may have been due to an increased rate of thromboembolic events in the treatment arm [81].”
BackgroundMoussouttas, M., Malhotra, R., Fernández-Salazar, L. I., Maltenfort, M., Holowecki, M., Delgado, J. R., Lawson, N., & Badjatia, N. (2009) · Neurocritical Care · doi:10.1007/s12028-009-9290-0 · Cited by 55
“Also excluded were patients <18 years old, those enrolled in the Factor Seven for Acute Hemorrhagic Stroke Trial [14], those undergoing surgical evacuation prior to the second CT, patients with posterior fossa ICH (due to the possible limitation in hematoma expansion as a result of anatomic restrictions), and those la…”
MethodOutcome of intracerebral haemorrhage patients pre‐treated with statins
Gomis, M., Ois, Á., Rodríguez-Campello, A., Cuadrado‐Godia, E., Jiménez-Conde, J., Subirana, I., Dávalos, A., & Roquer, J. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02838.x · Cited by 53
Unmet Needs and Challenges in Clinical Research of Intracerebral Hemorrhage
Selim, M. H., Hanley, D. F., Broderick, J. P., Goldstein, J. N., GREGSON, B. A., Falcione, G., Gonzales, N. R., Gurol, M. E., Kersten, J., Lewkowicz, H., et al. (2018) · Stroke · doi:10.1161/strokeaha.117.019541 · Cited by 54
Self-citationHematoma expansion is more frequent in deep than lobar intracerebral hemorrhage
Roh, D. J., Boehme, A. K., Young, C., Roth, W., Gutierrez, J., Flaherty, M. L., Rosand, J. M., Testai, F. D., Woo, D., & Elkind, M. S. V. (2020) · Neurology · doi:10.1212/wnl.0000000000010990 · Cited by 51
Warkentin, L. M., Auriat, A. M., Wowk, S., & Colbourne, F. (2010) · Brain Research · doi:10.1016/j.brainres.2009.10.058 · Cited by 50
“Unfortunately, efforts to limit hematoma growth have not convincingly improved outcome (Mayer et al., 2008).”
Therapeutic strategies for intracerebral hemorrhage
Li, Z., Khan, S., Liu, Y., Wei, R., Yong, V. W., & Xue, M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1032343 · Cited by 57
“The results of phase II clinical trial of recombinant factor VIIa show that treatment within 4 h after the onset of ICH limited hematoma expansion and improved clinical regression, but the incidence of thromboembolic events was mildly increased (84).”
BackgroundYassi, N., Zhao, H. H., Churilov, L. P., Wu, T. Y., Ma, H., Nguyen, T. H., Cheung, A. K., Meretoja, A., Mai, D. T., Kleinig, T. J., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00128-5 · Cited by 51
Self-citationTyan, Y., Wu, M.-C., Chin, C.-L., Kuo, Y., Lee, M.-S., & Chang, H.-Y. (2014) · International Journal of Biomedical Imaging · doi:10.1155/2014/947539 · Cited by 50
Hematoma Volume Measurement in Gradient Echo MRI Using Quantitative Susceptibility Mapping
Wang, S., Lou, M., Liu, T., Cui, D., Chen, X., & Wáng, Y. (2013) · Stroke · doi:10.1161/strokeaha.113.001638 · Cited by 50
Surgical Trials in Intracerebral Hemorrhage
Vespa, P. M., Martin, N. A., Zuccarello, M., Awad, I. A., & Hanley, D. F. (2013) · Stroke · doi:10.1161/strokeaha.113.001494 · Cited by 50
Kang, D., Kim, C. K., Jeong, H., Soh, M., Kim, T., Choi, I.-Y., Ki, S., Kim, D. Y., Yang, W., Hyeon, T., et al. (2017) · Nano Research · doi:10.1007/s12274-017-1478-6 · Cited by 55
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.